Silvia Coronel , Shamili Allam, Neha Teekappanavar, Ahmed Abdelhalim, Sivagini Ganesh, Wafaa Elatre, Michael Koss, Janice Liebler, Richard Barbers, Alison Wilcox, Bonnie Garon, Zea Borok, Billy Peng and Ahmet Baydur*
Background: The 2019 update by the ISHLT of classification for CLAD includes a mixed and undefined phenotype.
Objectives: Assess (a) frequency phenotypes (per ISHLT) with emphasis on double lung transplants (DLTxs), (b) concordance spirometry with imaging and transbronchial biopsy findings, (c) mortality rates amongst phenotypes.
Methods: Single-center retrospective study of adult patients. Time from transplant to CLAD and mortality amongst phenotypes compared by ANOVA adjusted for age, gender and BMI.
Results: Of 360 patients, 96 (27%) met criteria for CLAD (57 DLTx). Seventy-four (77%) experienced combined FEV1 and FVC decline. In DLTxs, onset of FEV1 decline (n=12) occurred 10 months earlier than for FVC (n=4) and 5 months before simultaneous onset of FVC and FEV1 decline (n=41). Amongst DLTxs, largest cohort was mixed group (n=30, 53%); RAS phenotype second largest (n=16, 28%). Median onset of CLAD: 30 months for BOS and mixed categories (combined n=34); 48 months for RAS (n=16). Time to death following DLTx: longest in BOS, shortest in RAS, intermediate in mixed phenotypes.
Conclusion: CLAD occurs in more than one-quarter of patients; three-fourths exhibit concurrent decline in FEV1 and FVC. Imaging detects changes when biopsy findings are mild or not identified and often do not reflect spirometric changes.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 